Introduction: India has made a significant advancement in its healthcare capabilities by developing an indigenous RT-PCR testing kit for Monkeypox. The kit, named the IMDX Monkeypox Detection RT-PCR Assay, was developed by Siemens Healthineers and has received approval from the Central Drugs Standard Control Organisation (CDSCO). This innovation is a major boost for the “Make in India” initiative and a vital step in the country’s fight against the Monkeypox public health emergency.
BulletsIn
- Indigenous Development: India has developed its own RT-PCR testing kit for Monkeypox, demonstrating a major milestone in local healthcare innovation.
- CDSCO Approval: The IMDX Monkeypox Detection RT-PCR Assay has been approved for manufacturing by the Central Drugs Standard Control Organisation (CDSCO).
- Manufacturer: The kit is developed by Siemens Healthineers, a leading medical technology company.
- Manufacturing Location: The RT-PCR kits will be manufactured at Siemens’ molecular diagnostics unit in Vadodara, India, with a production capacity of 1 million reactions annually.
- Rapid Results: The kit provides results in just 40 minutes, significantly faster than traditional methods, which typically take 1-2 hours.
- High Sensitivity and Specificity: The assay is clinically validated by ICMR-National Institute of Virology, Pune, with 100% sensitivity and specificity.
- Adherence to Standards: The IMDX Monkeypox Detection RT-PCR Assay complies with Indian statutory guidelines and global standards.
- Health Emergency Context: The development comes in response to the World Health Organization’s (WHO) declaration of Monkeypox as a public health emergency of international concern.
- New Virus Strain: The emergence of a new strain of Monkeypox (Clad-1) has increased transmissibility and higher mortality rates, necessitating prompt diagnostics.
- Focus on ‘Access to Care’: Siemens emphasizes the importance of accessible healthcare and timely diagnostics to combat the Monkeypox outbreak effectively.
